<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03760718</url>
  </required_header>
  <id_info>
    <org_study_id>19021</org_study_id>
    <nct_id>NCT03760718</nct_id>
  </id_info>
  <brief_title>Chloroprocaine Lavage to Improve Outcomes Related to Operative Cesarean Delivery</brief_title>
  <acronym>CLOR-PRO</acronym>
  <official_title>Chloroprocaine Lavage to Improve Outcomes Related to Operative Cesarean Delivery</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Oregon Health and Science University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Oregon Health and Science University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>Yes</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      The long term objective is to show that intraperitoneal chloroprocaine can be used an&#xD;
      alternative option to avoid general anesthesia during cesarean delivery, to alleviate&#xD;
      mother's discomfort from surgical pain, reduce complications, and improve the birth&#xD;
      experience. The objectives in this study are to determine the amount of chloroprocaine that&#xD;
      is absorbed into the blood in order to create a plasma concentration time profile and to&#xD;
      determine the incidence of side effects to help guide selection of an appropriate&#xD;
      concentration for future study.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Compared to general anesthesia, neuraxial anesthesia (spinals and epidurals) is associated&#xD;
      with a lower risk for maternal aspiration and airway compromise, exposes the baby to less&#xD;
      anesthetic, and allows for greater maternal involvement in the birth process. For these&#xD;
      reasons, it has become the preferred method of anesthesia for cesarean delivery. Spinals that&#xD;
      are placed to facilitate cesarean delivery have a duration of one to two hours. Currently, if&#xD;
      that duration is exceeded patients must have general endotracheal anesthesia. In addition,&#xD;
      suboptimal neuraxial anesthesia for cesarean delivery is not uncommon with an incidence of&#xD;
      2-9%, depending upon the urgency of surgery and the type of neuraxial block. Providing less&#xD;
      than adequate anesthesia for cesarean delivery may increase the risk of legal liability. For&#xD;
      this reason, some patients with suboptimal neuraxial anesthesia have intraoperative&#xD;
      conversion to general endotracheal anesthesia.&#xD;
&#xD;
      The first known description of the use of intraperitoneal local anesthetic to provide&#xD;
      anesthesia for cesarean delivery was published in 1975. In this article Ranney et al.&#xD;
      described how to use up to 100 mL of 1% procaine to provide anesthesia for cesarean delivery&#xD;
      under local field block alone. Some of this was injected into the skin and fascia, and the&#xD;
      remainder was diluted to 0.5% and &quot;spilled&quot; into the peritoneum.&#xD;
&#xD;
      Multiple publications have shown that intraperitoneal local anesthetic can be used to treat&#xD;
      intraoperative and postoperative pain, prevent postoperative nausea, and shorten hospital&#xD;
      length of stay. A recently published 40-month case series showed that chloroprocaine lavage&#xD;
      can be used as part of a multimodal approach to treating intraoperative pain. In this case&#xD;
      series, the technique of chloroprocaine lavage helped investigators to avoid general&#xD;
      endotracheal anesthesia in 32 women having a cesarean delivery.&#xD;
&#xD;
      In this case series, no patients exhibited clinical signs of systemic local anesthetic&#xD;
      toxicity. It is believed that chloroprocaine has a limited potential for toxicity because of&#xD;
      its short plasma half-life, which is only 11-21 seconds. The purpose of this study is to&#xD;
      determine the amount of chloroprocaine that is taken up into the blood stream after&#xD;
      intraperitoneal administration to ensure that blood levels are low and do not raise a safety&#xD;
      concern. Data obtained from this study will help to define a safe dose of chloroprocaine for&#xD;
      intraperitoneal administration.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">September 30, 2019</start_date>
  <completion_date type="Anticipated">December 31, 2021</completion_date>
  <primary_completion_date type="Actual">September 17, 2020</primary_completion_date>
  <phase>Early Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Chloroprocaine plasma concentration at 1 minute</measure>
    <time_frame>1 minute after intraperitoneal chloroprocaine administration</time_frame>
    <description>The chloroprocaine plasma concentration obtained from a venous sample 1 minute after intraperitoneal chloroprocaine administration.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Chloroprocaine plasma concentration at 5 minutes</measure>
    <time_frame>5 minutes after intraperitoneal chloroprocaine administration</time_frame>
    <description>The chloroprocaine plasma concentration obtained from a venous sample 5 minutes after intraperitoneal chloroprocaine administration.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Chloroprocaine plasma concentration at 10 minutes</measure>
    <time_frame>10 minutes after intraperitoneal chloroprocaine administration</time_frame>
    <description>The chloroprocaine plasma concentration obtained from a venous sample 10 minutes after intraperitoneal chloroprocaine administration.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Chloroprocaine plasma concentration at 20 minutes</measure>
    <time_frame>20 minutes after intraperitoneal chloroprocaine administration</time_frame>
    <description>The chloroprocaine plasma concentration obtained from a venous sample 20 minutes after intraperitoneal chloroprocaine administration.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Chloroprocaine plasma concentration at 30 minutes</measure>
    <time_frame>30 minutes after intraperitoneal chloroprocaine administration</time_frame>
    <description>The chloroprocaine plasma concentration obtained from a venous sample 30 minutes after intraperitoneal chloroprocaine administration.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Adverse Events</measure>
    <time_frame>Within 4 hours of intraperitoneal chloroprocaine administration</time_frame>
    <description>Adverse experience reporting will include the following: seizures, tinnitus, metallic taste, anxiety, agitation, muscle twitching, drowsiness, respiratory depression, dizziness, nausea, vomiting, vision changes, paresthesias, perioral numbness, hypotension, arrhythmias, and cardiac arrest.</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">15</enrollment>
  <condition>Cesarean Section</condition>
  <arm_group>
    <arm_group_label>Preservative free Chloroprocaine Group 1</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>40 ml of preservative-free 1% chloroprocaine</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Preservative free Chloroprocaine Group 2</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>40 ml of preservative-free 2% chloroprocaine</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Preservative free Chloroprocaine Group 3</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>40 ml of preservative-free 3% chloroprocaine</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Preservative free 1% Chloroprocaine</intervention_name>
    <description>40 ml of preservative-free 1% chloroprocaine is planned for administration into the peritoneal cavity after delivery of the baby.</description>
    <arm_group_label>Preservative free Chloroprocaine Group 1</arm_group_label>
    <other_name>Nesacaine</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Preservative free 2% Chloroprocaine</intervention_name>
    <description>40 ml of preservative-free 2% chloroprocaine is planned for administration into the peritoneal cavity after delivery of the baby.</description>
    <arm_group_label>Preservative free Chloroprocaine Group 2</arm_group_label>
    <other_name>Nesacaine</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Preservative free 3% Chloroprocaine</intervention_name>
    <description>40 ml of preservative-free 3% chloroprocaine is planned for administration into the peritoneal cavity after delivery of the baby.</description>
    <arm_group_label>Preservative free Chloroprocaine Group 3</arm_group_label>
    <other_name>Nesacaine</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Subjects ≥ 18 to 50 years of age having scheduled cesarean sections on 12C (Labor and&#xD;
             Delivery) within Oregon Health &amp; Science University (OHSU).&#xD;
&#xD;
          -  Only subjects having spinal anesthesia will be eligible.&#xD;
&#xD;
          -  Only subjects that can have a Pfannenstiel incision will be enrolled.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Subjects with chronic narcotic usage&#xD;
&#xD;
          -  Subjects that are deemed to need a combined spinal epidural for any reason.&#xD;
&#xD;
          -  Subjects who are unable to successfully get a spinal block&#xD;
&#xD;
          -  Subjects with known atypical cholinesterase activity&#xD;
&#xD;
          -  American Society of Anesthesiologist physical status IV or higher&#xD;
&#xD;
          -  Subjects with contraindication to neuraxial anesthesia (coagulopathy, infection)&#xD;
&#xD;
          -  Subjects with stage 4 chronic kidney disease or worse (eGFR &lt; 30 ml/min)&#xD;
&#xD;
          -  Subjects with significant hepatic dysfunction (AST or ALT &gt; 2x the upper limit of&#xD;
             normal)&#xD;
&#xD;
          -  Subjects with allergies to drugs required for this protocol.&#xD;
&#xD;
          -  Subjects with multifetal gestations&#xD;
&#xD;
          -  Subjects with a BMI &gt; 40 kg/m2&#xD;
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>50 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Brandon M Togioka, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Oregon Health and Science University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>OHSU Labor and Delivery; Oregon Health and Science University Hospital</name>
      <address>
        <city>Portland</city>
        <state>Oregon</state>
        <zip>97239</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <reference>
    <citation>Ranney B, Stanage WF. Advantages of local anesthesia for cesarean section. Obstet Gynecol. 1975 Feb;45(2):163-7.</citation>
    <PMID>1118089</PMID>
  </reference>
  <verification_date>October 2021</verification_date>
  <study_first_submitted>November 9, 2018</study_first_submitted>
  <study_first_submitted_qc>November 29, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">November 30, 2018</study_first_posted>
  <last_update_submitted>October 5, 2021</last_update_submitted>
  <last_update_submitted_qc>October 5, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">October 13, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Oregon Health and Science University</investigator_affiliation>
    <investigator_full_name>Brandon M Togioka</investigator_full_name>
    <investigator_title>Principal Investigator</investigator_title>
  </responsible_party>
  <keyword>chloroprocaine</keyword>
  <keyword>cesarean delivery</keyword>
  <keyword>lavage</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Chloroprocaine</mesh_term>
    <mesh_term>Procaine</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol and Statistical Analysis Plan</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>November 30, 2018</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/18/NCT03760718/Prot_SAP_000.pdf</document_url>
    </provided_document>
  </provided_document_section>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

